{"url_path":"/sec/kpti/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1503802/0001193125-26-222808-index.html","accession_number":"0001193125-26-222808","cik":"0001503802","ticker":"KPTI","issuer_name":"Karyopharm Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1503802/0001193125-26-222808-index.html","primary_entity_key":"0001503802","primary_entity_name":"Karyopharm Therapeutics Inc."},"word_count":153,"has_tables":true,"body_markdown":"Item 2.02\n\nResults of Operations and Financial Condition.\n\nOn May 14, 2026, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}